996-P: Correlation of GMI with HbA1c in People Living with Diabetes over Time

Introduction 54.5) ys, A1c 7.7(7.1; 8.4)%, GMI 7.4(6.8; 8.0)%, 46% women. CGM data of the 14-days prior to each A1c were used. We used A1c/GMI at baseline(BL), the 2 follow-ups(FU2, FU3) and the last available measurement(LT). The difference between A1c and GMI over time was assessed and is indicated as delta-GMI-A1c. An absolute delta 0.5% was considered relevant. Results: 30.1%(n=34) had a stable relationship between GMI and A1c over time. Comparing trajectories between the three baseline groups, BL+(GMIA1c, n=14/12.4%), BL=(GMI=A1c, n=60/53.1%) and BL-(GMIA1c, n=39/34.5%), BL= has the largest portion of stable relationship (n=20/33.3%) vs. BL-(n=11/28.2%) vs. BL+(n=3/21.4%). 8.8%(n=8) switched to stable correspondence after baseline (8/20.5%(BL-);2/14.3%(BL+)). Conclusion: A1c and GMI vary between individuals and baseline groups, with 30% having a stable relationship over time. Our data support using CGM to assess glycemia and highlight the need on the association of CGM on long-term outcome. Disclosure J.K. Mader: Advisory Panel; Becton, Dickinson and Company. Speaker's Bureau; Becton, Dickinson and Company, A. Menarini Diagnostics, Boehringer-Ingelheim, diaTribe. Other Relationship; Diabetes UK. Stock/Shareholder; decide Clinical Software GmbH. Advisory Panel; embecta. Speaker's Bureau; embecta, Viatris Inc., Eli Lilly and Company. Advisory Panel; Eli Lilly and Company, Medtronic. Speaker's Bureau; Medtrust. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Advisory Panel; PharmaSens, Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care. Board Member; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Sanofi-Aventis Deutschland GmbH, Sanofi, Dexcom, Inc., Viatris Inc. Advisory Panel; Viatris Inc. Speaker's Bureau; Ypsomed AG. Research Support; European Union. Stock/Shareholder; elyte Diagnostics GmbH. Other Relationship; elyte Diagnostics GmbH. Board Member; European Association for the Study of Diabetes. Research Support; European Union Aviation Safety Agency. P.M. Baumann: None. M. Cigler: None. T. Poettler: None. M. Oberosler: None. J. Gruber: None. S. Kheir: None. C. Harer: Other Relationship; Novo Nordisk, Eli Lilly and Company, Viatris Inc., Kelcon GmbH. R. Meçani: None. H. Sourij: Advisory Panel; Amarin Corporation. Speaker's Bureau; Amgen Inc., Amarin Corporation, Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novartis AG. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Sanofi. Speaker's Bureau; Sanofi. Consultant; K:Businesscom.